Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 3.0 | 5.0 |
Min SIP Amount | ₹500 | ₹100 |
Expense Ratio | 2.35 | 1.91 |
NAV | ₹15.50 | ₹36.58 |
Fund Started | 18 Oct 2021 | 25 Jun 2018 |
Fund Size | ₹213.78 Cr | ₹5295.32 Cr |
Exit Load | Exit load of 1% if redeemed within 12 months. | Exit load of 1% if redeemed within 15 days. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 15.38% | 20.33% |
3 Year | 19.44% | 24.92% |
5 Year | - | 24.75% |
1 Year
3 Year
5 Year
Equity | 97.95% | 98.28% |
Cash | 2.05% | 1.72% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 16.22% |
Divi's Laboratories Ltd. | 5.96% |
Lupin Ltd. | 5.78% |
Suven Pharmaceuticals Ltd. | 5.39% |
Apollo Hospitals Enterprise Ltd. | 5.16% |
Max Healthcare Institute Ltd. | 5.07% |
Torrent Pharmaceuticals Ltd. | 4.11% |
Aurobindo Pharma Ltd. | 3.61% |
Mankind Pharma Ltd. | 3.09% |
Alkem Laboratories Ltd. | 2.84% |
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 13.50% |
Dr. Reddy's Laboratories Ltd. | 8.95% |
Cipla Ltd. | 8.85% |
Divi's Laboratories Ltd. | 6.71% |
Aurobindo Pharma Ltd. | 5.30% |
Lupin Ltd. | 4.73% |
Alkem Laboratories Ltd. | 4.42% |
Mankind Pharma Ltd. | 3.50% |
Gland Pharma Ltd. | 3.39% |
Zydus Lifesciences Ltd. | 3.10% |
Name | Dhimant Shah | Dharmesh Kakkad |
Start Date | 01 Dec 2022 | 23 Feb 2021 |
Name
Start Date
Description | The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 18 Oct 2021 | 25 Jun 2018 |
Description
Launch Date